yes, VRX and ALXN causing some issues + maybe end of ASCO selling. Nothing to do with ARNA, so maybe a buy opportunity.
I'm not sure how the market will interpret this news, but since it's a new and small indication and not an indication ACHN has mentioned they were targeting, it's probably not a factor. It's nice that ALXN is preparing the way for ACHN. Let's hope we have a better mouse trap.
IMO you might want to do some research on ACHN. I would be interested in your opinion.
Failed top line results in a new ultra rare indication myasthenia gravis (gMG). Probably no effect but worth mentioning.
hopefully true, but ARNA has had a tail wind of the market and sector the past few weeks, so his start timing was good. I'm waiting to hear the great OZ speak...
definitely an interesting hire. Maybe he can also help combat against the large short.
I've been reporting abuse on many of the fake ID's. Maybe Yahoo finally woke up, but doubtful. Click on report abuse then ignore.
Pasted from a Boston Globe article:
Drugs for rare diseases are far more likely to succeed, with 25 percent of rare disease drugs that enter clinical trials getting FDA approval. The lowest rates of success are seen in chronic diseases with large patient populations, which have an average success rate of 8.7 percent.